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Abstract
Aim Our aim was to set up a system to help UK clinical
research units to prevent healthy volunteers from participat-
ing in more than one non-therapeutic trial simultaneously, or
from starting a second trial too soon after the first.
Methods TOPS (The Over-volunteering Prevention System)
is internet-based, simple and quick to use, free to users and a
charity run by a Board of Trustees. Users enter only two or
three pieces of information: (1) ‘National Insurance number’
(NINO) of UK citizens, or ‘passport number’ and country of
origin of non-UK citizens, as their identifier, (2) ‘date of last
dose’ of trial medicine or (3) ‘never dosed’. Subjects must
consent, but TOPS collects only non-personal data, so it
does not require Ethics Committee approval and is not
covered by the Data Protection Act.
Results A total of 55 research units (29 clinical research
organisations, 5 pharmaceutical companies, 13 universities
and 8 hospitals) throughout the UK have registered to use
TOPS, and have entered 124,906 volunteers since we
launched it. All commercial and many non-commercial
units now use TOPS. In our unit, no subject has to the best
of our knowledge participated in two trials simultaneously.
TOPS has reduced to <1% the incidence of subjects
attempting to volunteer within 3 months of completing
another trial elsewhere, and very few have to our know-
ledge succeeded.
Conclusion TOPS is widely used and effective, and helps
research units to comply with UK clinical trial regulations.
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Introduction
Healthy volunteers who take part in clinical trials are usually
paid for their time and inconvenience, so there has always
been concern that payment might tempt some to take part in
trials too frequently and become ‘professional volunteers’
[1], or ‘over-volunteers’ [2].
There are anecdotal reports of healthy subjects over-
volunteering, but no published data. Furthermore, there is
inconsistent guidance on the minimum time between two
trials. The Association of the British Pharmaceutical Indus-
try (ABPI) Guidelines [2] recommend 3 months, and longer
for a radioactive molecule or one with a long half-life; in
contrast, the USA Food & Drug Administration (FDA)
Guidelines [3] recommend 28 days.
During 1997–2001, we screened 6,998 healthy volunteers
for trials in our unit: 68 (0.97%; 58 men and 10 women) had
completed a trial elsewhere within the previous 3 months [4].
Theaverageintervalwas6weeks,butforsomesubjectsitwas
as short as 2 weeks. We detected over-volunteering by (1)
calling other units when we noticed recent forearm venepunc-
turemarks,remnantsofelectrocardiogram skinelectrodesstill
attached or a microcytic blood film; (2) other units calling us
for the same reasons; (3) learning from replies to our letters to
the subjects’ general practitioner (GP). The units involved
were contract research organisations (CROs), pharmaceutical
companies and universities, in different parts of the UK.
Healthy subjects rarely derive therapeutic benefit from
taking part in a clinical trial, so the risk of harm must be
minimal [2]. Anyone who takes part in two trials simulta-
neously, or even takes part in a trial too soon after a previous
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(The Over-volunteering Prevention System).
We thought that for such a system to be used widely by
both commercial and non-commercial units, it must: be
simple, quick to use, internet-based, secure, and reliable;
protect the anonymity of the subject; reveal no information
of commercial interest; carry no advertising; be free to all
types of user; be low-cost to set up and run.
Methods
Design
An ideal system would completely identify volunteers and
track all studies that they undertake. We considered the
subject’s name, photograph, fingerprint [5] and iris [6]a s
ideal identifiers, but rejected them all because:
& users would have to buy a software licence and recog-
nition equipment for fingerprint or iris recognition, and
& making available a volunteer’s private details to all users is
unreasonable and would require ethics committeeapproval
and compliance with the Data Protection Act [7].
Therefore, to protect the volunteer’s privacy, TOPS stores
minimal information:
& National Insurance number (NINO) of UK citizens, or
passport number and country of origin of non-UK citi-
zens, as a unique identifier, and
& date of last dose of trial medicine, or that the volunteer
was never dosed.
Everyone who works or claims benefits in the UK must
have a NINO, which is unique and permanent for each
person [8]. The UK government gave us permission to use
NINO.
To encourage wide use, TOPS is: internet-based; simple
and quick to use;secure; free from information of commercial
interest; validated according to Good Automated Manufactur-
ing Practice [9]; free to all users. The TOPS database is stored
in SQL Server. Users access the database indirectly through a
web browser. The website https://www.tops.org.uk uses https
to identify itself and to encrypt all data transferred across the
internet.
Our aim was to avoid TOPS being linked to our unit, lest
that deter other commercial units from using it. We failed to
find an independent organisation to sponsor and run TOPS,
so we registered it as a charity with a Board of Trustees [10],
and we run it ourselves. Most of the members of the Board
of Trustees are independent of our unit.
Since 2000, the cost of setting up and running TOPS,
excluding our time, has been £25,995 (€30,154), almost all
of which has been for the website host.
Using TOPS
Potential users request (enquiries@TOPS.org.uk)au s e r -
name and password. Contact details (name, phone number
and email address) of each organisation are stored to facil-
itate contact among users.
Users must obtain the volunteer’s permission to store
information about them. TOPS records the current date as
the registration date and notifies the user of any previous
entry for that volunteer, the date of the last dose (or that they
were never dosed) and the unit concerned. If there is no
previous entry or there is an acceptable interval since the last
dose (or they were never dosed), the user proceeds to screen
the volunteer. If there is a previous entry that suggests over-
volunteering, the user contacts the unit that made the last
entry. If over-volunteering is confirmed, the user rejects the
volunteer.
When a user enters the date of the last dose, there is a box
to tick to warn other users that the study is an unusually long
one,suchasone with a monoclonalantibodyorone involving
radioactivity.
We define over-volunteering as a subject attending for
screening within 3 months of completing a previous study.
TOPS does not distinguish between volunteers who received
active treatment and those who received placebo in a previous
study because it is usually impossible to obtain this informa-
tion within 3 months after the study.
The number of trials that a subject may take part in during
any 12-month period will depend on the circumstances
(Table 1).
Results
Since we launched TOPS in 2002, 55 units (Fig. 1) have
registered to use it: 29 CROs, 5 pharmaceutical companies,
13 universities and 8 hospitals, throughout the UK (Fig. 2).
Table 1 Guidance on the use of healthy volunteers
a
The number of trials that a subject may take part in during any 12-month
period will depend on the:
￿ Types of investigational medicinal product (IMP) and their half-lives
￿ Routes of administration of the IMP
￿ Frequency and duration of exposure to IMP
￿ Procedures involved
￿ Total volume of blood taken from the subject
￿ Amount of radioactivity (no more than 10 milliSievert).
In general, subjects should not receive an IMP systemically less than
3 months after the previous one
aFrom Association of the British Pharmaceutical Industry (ABPI)
guidelines for phase 1 clinical trials, 2007 [2]
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registered to use TOPS. Users entered 124,806 subjects in
TOPS between 2002 and mid-2011. CROs are the biggest
users, contributing 116,843 (93.6%) of all entries.
Table 2 summarises our experience of over-volunteering
in the period 1997–2011. In the first 2 years after we started
using TOPS, potential over-volunteers increased from about
1% to a peak of 4.6%. Thereafter, there was a progressive fall,
and in the last few years the incidence has been <1%. Table 3
shows that we now find most potential over-volunteers by
using TOPS.
Table 2 alsoshowsbyhowmuchthe incidence ofpotential
over-volunteers in our unit is reduced if over-volunteering is
defined as <1 month or <2 months between trials. An interval
of <2 months reduces the incidence only slightly, while an
interval of <1 month reduces the incidence substantially, to
0.2–0.5% in recent years.
We have other examples of the effectiveness of TOPS.
Several subjects have volunteered for trials in our unit, but
TOPSshowedthattheywerestilltakingpartintrialselsewhere.
Some GPs have informed us that their patients had not taken
part in a trial in the previous 3 months, but TOPS showed that
they had. On the other hand, some GPs have informed us that
their patients had taken part in a trial in the previous 3 months,
whereas TOPS showed that they had been registered but never
dosed, so we could recruit them. The reasons why they had not
been dosed included not meeting the protocol selection criteria
or cancellation of the studies.
Discussion
We were surprised by the increase in our detection of over-
volunteering during the first 2 years after the introduction of
TOPS and attribute this increase to the efficacy of TOPS
compared with our former methods of detection. Almost
certainly, TOPS helped identify potential over-volunteers
whom we would previously have missed. After the initial
surge, the incidence of over-volunteering fell. As the uptake
of TOPS increased, it not only helped us to identify potential
over-volunteers, but also acted as a deterrent as volunteers
became aware of its efficiency. Other units have had similar
experiences.
Currently, only a few subjects attempt to volunteer for our
studies within <3 months after completing one elsewhere.
Adoptinga 2-monthinterval,whichwould probably be enough
for most studies of small molecules, reduces the calculated
incidence only slightly. A 1-month interval, as recommended
by the FDA [3], reduces the incidence substantially, but most
UK investigators would agree that 1 month is insufficient.
Fig. 1 Cumulative number of
UK users of TOPS since its
launch in 2002
Fig. 2 Locations of TOPS users
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one of our trials while taking part in another elsewhere.
However, a few subjects have succeeded in starting a trial
in our unit within 28 days after the last dose in trials in other
units. Those units had just started to use TOPS, but were not
doing so consistently, otherwise TOPS would have identi-
fied the subjects as potential over-volunteers.
Not all attempts to over-volunteer are intentional. Some
subjects genuinely misunderstand instructions about not
leaving too short an interval between trials, or overestimate
the interval since their last study.
We have been surprised by some replies from GPs to our
requests for information about their patients. Occasionally
GPs tell us that the patient has not done a trial within the
previous 3 months, when TOPS shows that they have (false
negative), and occasionally GPs tell us that the patient has
done a trial within the previous 3 months, when TOPS shows
that they were screened but never dosed (false positive). We
have several examples of each, which clearly demonstrate
that a reply from the GP alone is not sufficient to prevent
over-volunteering and that it can falsely incriminate a
volunteer.
The success ofTOPS depends upon users registering every
volunteer and cooperating with each other when over-
volunteering is suspected. In our experience, cooperation has
been good.
Two systems with aims similar to TOPS are used in some
other EU countries.
1. VIP (Volunteer Inclusion Period) Check [11]i sp r i v a t e l y
owned system based in Germany. Users enter the volun-
teer’s full name, date of birth, sex, nationality, start and
end dates ofthe study and whether it involvesexposureto
radioactivity. Users pay fees that depend on usage. VIP
Table 2 Number of healthy
subjects who came for screening
at our unit, and the number
and percentage of these who
attempted to volunteer for a trial
within 3, 2 or 1 months of
completing a previous trial
aTOPS launched in 2002
bFirst half of year only
Year Number of volunteers
who came for screening
Number (%) of volunteers completing a trial elsewhere within the
previous:
3 months 2 months 1 month
1997–2001 6,998 68 (1.0) 56 (0.8) 31 (0.4)
2002
a 1,490 52 (3.5) 43 (2.9) 22 (1.5)
2003 1,811 83 (4.6) 62 (3.4) 23 (1.3)
2004 1,092 18 (1.6) 15 (1.4) 9 (0.8)
2005 836 20 (2.4) 14 (1.7) 8 (1.0)
2006 1,583 38 (2.4) 27 (1.7) 14 (0.9)
2007 1,257 20 (1.6) 14 (1.1) 3 (0.2)
2008 1,349 13 (1.0) 11 (0.8) 5 (0.4)
2009 767 5 (0.7) 5 (0.7) 3 (0.4)
2010 1,114 9 (0.8) 9 (0.8) 6 (0.5)
2011
b 990 5 (0.5) 5 (0.5) 2 (0.2)
Table 3 Number and methods of detecting healthy subjects who attempted to volunteer for a trial in our unit within 3 months of completing a
previous trial
Methods Year
1997–2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
a
TOPS
b –– 37 12 17 30 14 13 3 8 5
Signs
c 0 1 3 240000000
We called other CROs 34 18 11 11110000
Other CROs called us 15 19 22 10110100
Volunteer admitted when challenged 7 1301110010
GP replies 12 1801530100
Total 68 52 83 18 20 38 20 13 5 9 5
a
CRO, Contract research organisation; GP, general practitioner
aFirst half of year only
bTOPS was launched in 2002; no potential over-volunteer was identified by TOPS in that year
cVenepuncture marks on forearm, electrocardiogram electrode marks (or electrodes still in place) or haematology results
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for 60 days before and 60 days after completing one, as
well as participation in more than one study at a time. It is
currently used by 22 units (17 CROs, 2 pharmaceutical
companies and 3 university units) in Germany, Belgium,
Netherlands and Switzerland [12]. Only 40,000 volun-
teers have been entered in VIP Check since 2000 [12],
which would suggest that it is not used regularly. No
information is available about whether VIP Check pre-
vents over-volunteering.
2. VRB (Volontaires pour la Recherche Biomédicale) [13]
is a French national database run by the Ministry of
Health. It is web-based, mandatory to use according to
French law [14] and free to users. Users must enter the
volunteer’s Social Security number and initials, the start
and end dates of the study and payment. The maximum
that a volunteer can earn in a year is €4,500, and there is
a post-study exclusion period. There is no published
information about the usage of VRB or whether it
prevents over-volunteering.
A recent report claimed that healthy subjects travel to
Belgium from nearby EU countries to take part in phase 1
trials (‘tourist volunteers’). This report led to a call for a
single mandatory system to prevent over-volunteering
throughout the EU [12]. We have no evidence that healthy
subjects travel from other EU countries just to volunteer for
a clinical trial in our unit. However, unlike NINO, a passport
number is not for life, so if we have any concerns about the
validity of a non-UK volunteer, our policy is not to recruit
them. Cultural differences on storing personal information
would make it difficult to implement a single EU system.
Funding would be needed to set up, maintain and run the
system. TOPS is a low-cost system that is free to all users,
and it serves the UK well; as such, there seems little reason
to change it. The UK is the only country in the world with a
widely used system to prevent over-volunteering.
Could TOPS be improved? A biometric identifier would
improve TOPS but, although technology has advanced and
costs have reduced since we set up TOPS, costs would still
limit its use substantially. TOPS usage could be extended to
other countries, particularly those in which citizens have
identity cards. Identity cards are the norm in many EU
countries, and in some, such as Belgium [15], people must
carry their identity cards at all times.
Since TOPS was launched, UK regulations [16, 17]h a v e
required investigators to have procedures to prevent over-
volunteering.TOPShelpsunitstocomplywiththese.Arecent
UK bioethics report called for mandatory use of TOPS [18].
In conclusion, only a few healthy subjects now attempt to
over-volunteer in our unit, and to the best of our knowledge
very few succeed. TOPS not only helps to prevent over-
volunteering, but also deters subjects from trying to do so.
TOPS makes recruiting volunteers more efficient, prevents
unnecessary screening of volunteers, and helps units to
comply with UK regulations. Feedback from other units is
required to determine whether our findings apply to UK
units in general.
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